ProMIS Neurosciences Plunges 14.39% Amid Funding Announcement

On July 28, 2025, ProMIS Neurosciences experienced a significant drop of 14.39% in pre-market trading, marking a notable decline in its stock performance.

ProMIS Neurosciences recently secured $12 million in financing through a combination of private placement of warrants and the exercise of existing warrants. This funding is expected to support the company's ongoing research and development efforts, particularly in the field of Alzheimer's disease treatment.

The financing round included $3 million from a private placement of warrants and an additional $9 million from the exercise of existing warrants. This strategic move is aimed at bolstering the company's financial position and accelerating its pipeline of innovative therapies.

ProMIS Neurosciences has also reported material events related to its funding assumptions, including plans for an $80 million equity raise in the second half of 2025 and a total of $1.3 billion through 2030. These financial projections indicate the company's ambitious goals and its commitment to advancing its therapeutic programs.